D.A. Davidson & CO. Has $59.81 Million Stake in Johnson & Johnson (JNJ)
D.A. Davidson & CO. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 2.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 492,907 shares of the company’s stock after selling 10,382 shares during the quarter. Johnson & Johnson makes up 1.2% of D.A. Davidson & CO.’s portfolio, making the stock its 10th biggest holding. D.A. Davidson & CO.’s holdings in Johnson & Johnson were worth $59,809,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after acquiring an additional 7,853,141 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Johnson & Johnson by 1.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after acquiring an additional 541,338 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Johnson & Johnson by 3.8% in the second quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after acquiring an additional 478,982 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Johnson & Johnson by 4.5% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock worth $1,089,415,000 after acquiring an additional 387,504 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Johnson & Johnson by 9.5% in the first quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock worth $967,793,000 after acquiring an additional 654,350 shares during the last quarter. 66.06% of the stock is owned by institutional investors.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $145.96, for a total value of $38,601,311.40. Following the sale, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at approximately $70,243,833.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 349,805 shares of company stock valued at $50,593,707. 0.22% of the stock is owned by company insiders.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the previous year, the business earned $1.90 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
JNJ has been the subject of several analyst reports. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group set a $149.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $142.54.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Stock Split
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.